Measure tumor response
to assess changes in genomic alterations after treatment initiation.2,3
The only tissue-free biopsy to measure treatment response.1
>50% reduction in ctDNA is associated with
significantly longer progression-free survival (PFS).2,3
See treatment response in as soon as 4 weeks with just a simple blood test.1
*For patients with advanced solid tumor cancers, placed on immunotherapy.
Testing must occur 4-10 weeks after therapy initiation.1,2
Reduce ambiguity
between progression and
pseudo-progression when
using immunotherapy.2,3
Important note: Guardant360 Response was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Covered by Medicare
for all advanced
solid tumors.*